Effect of Vitamin E Fortified Whey Drink on Nutritional, Inflammatory and Oxidative Markers in Hemodialysis Patients
NCT ID: NCT02163070
Last Updated: 2015-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
92 participants
INTERVENTIONAL
2013-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Provision of Antioxidant Therapy in Hemodialysis (PATH) Study
NCT00237718
Supplemented Low Protein Diet and Progression of CKD
NCT03818568
To Explore the Anti-oxidative Effects and Inflammation Effects of Soy Protein to Renal Function of End Stage Diabetes Nephropathy Patients
NCT05840796
Effects of Low Protein Diet in Preventing the Progression of Chronic Kidney Disease(CKD)---a Prospective Study
NCT02886975
Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation
NCT00882401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. consumption of 220 milliliters of whey drink three times a week,
2. consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
3. consumption of 400 milligrams of vitamin E three times a week,
4. control group: no intervention. Patients were followed for 2 months. At the beginning and the end of the 2-month intervention period, 10 milliliters of blood were taken from all of the patients and nutritional status of the patients were assessed as the primary outcome. Serum levels of malondialdehyde, c-reactive protein, albumin, transferrin and lipoproteins were also measured. SGA, MIS and SF-12 questionnaires were filled for all of the patients at the beginning and the end of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
whey drink fortified with vitaminE
consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
whey drink fortified with vitaminE
consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
vitaminE
consumption of 400 milligrams of vitamin E three times a week,
vitamin E
consumption of 400 milligrams of vitamin E three times a week,
D- control
control group: no intervention,
No interventions assigned to this group
whey drink
consumption of 220 milliliters of whey drink three times a week,
whey drink,
consumption of 220 milliliters of whey drink three times a week,
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
whey drink,
consumption of 220 milliliters of whey drink three times a week,
whey drink fortified with vitaminE
consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
vitamin E
consumption of 400 milligrams of vitamin E three times a week,
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment;
* be dialyzed at least 2 times a week for 3 months
Exclusion Criteria
* active infection;
* using immunosuppressant drugs or multi-vitamins;
* pregnancy, consuming whey or soy products
17 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Mohammad Hassan Eftekhari
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Hassan Eftekhari
professor. PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammad Hassan Eftekhari, professor
Role: STUDY_DIRECTOR
Shiraz University of Medical Sciences
References
Explore related publications, articles, or registry entries linked to this study.
Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
91-6424
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.